UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance

Cell Death Differ. 2021 Feb;28(2):671-684. doi: 10.1038/s41418-020-00616-8. Epub 2020 Sep 8.

Abstract

UBE2O, an E2/E3 hybrid ubiquitin-protein ligase, has been implicated in the regulation of adipogenesis, erythroid differentiation, and tumor proliferation. However, its role in cancer radioresistance remains completely unknown. Here, we uncover that UBE2O interacts and targets Mxi1 for ubiquitination and degradation at the K46 residue. Furthermore, we show that genetical or pharmacological blockade of UBE2O impairs tumor progression and radioresistance in lung cancer in vitro and in vivo, and these effects can be restored by Mxi1 inhibition. Moreover, we demonstrate that UBE2O is overexpressed and negatively correlated with Mxi1 protein levels in lung cancer tissues. Collectively, our work reveals that UBE2O facilitates tumorigenesis and radioresistance by promoting Mxi1 ubiquitination and degradation, suggesting that UBE2O is an attractive radiosensitization target for the treatment of lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Basic Helix-Loop-Helix Transcription Factors / metabolism*
  • Cell Line, Tumor
  • Disease Progression
  • Humans
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Proteolysis
  • Radiation Tolerance*
  • Tumor Suppressor Proteins / metabolism*
  • Ubiquitin-Conjugating Enzymes / antagonists & inhibitors
  • Ubiquitin-Conjugating Enzymes / metabolism*
  • Ubiquitination*
  • Xenograft Model Antitumor Assays

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • MXI1 protein, human
  • Tumor Suppressor Proteins
  • Ubiquitin-Conjugating Enzymes
  • UBE2O protein, human